scholarly journals Evaluation of Health Perceptions And Healthcare Utilization Among Population-Based Female Cancer Survivors And Cancer-Free Women

Author(s):  
Kate E Dibble ◽  
Maneet Kaur ◽  
Junrui Lyu ◽  
Avonne E Connor

Abstract Purpose. Cancer survivors are more likely to report having a poor health status when compared to the general population; however, few studies have focused on the impact of cancer on perceived health status, in combination with other healthcare utilization and access outcomes, among women from disadvantaged health populations.Methods. 25,741 women with and without a history of cancer from the National Health and Nutrition Examination Survey (NHANES) from 1999 to 2016 contributed data. Adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were estimated using multivariable logistic regression models for the associations between cancer status and healthcare utilization and access outcomes. Models were stratified by race/ethnicity, federal poverty level (FPL), education, and comorbidities. Results. A total of 2,415 (9.4%) women had a history of cancer with breast cancer as the most common site (n=704, 29.2%). While most survivors were non-Hispanic white (68.4%), 15.2% were Hispanic, 12.1% were non-Hispanic Black, and 4.3% were additional racial/ethnic groups. Survivors were 1.28 times more likely to report fair/poor perceived health status (95% CI, 1.09-1.50), 1.61 times more likely to report hospitalizations in the last year (95% CI, 1.40-1.86), and 1.37 times more likely to see a mental health provider within the last year (95% CI, 1.12-1.66) compared to controls. Race/ethnicity and FPL were the only significant effect modifiers.Conclusion. Our study identifies disparities in health status and healthcare utilization among female cancer survivors and recognizes the importance of evaluating these associations among disadvantaged health populations. These findings could inform future cancer survivorship care.

2019 ◽  
Vol 9 (6) ◽  
pp. 1208-1215
Author(s):  
Corinne R Leach ◽  
Rhyan N Vereen ◽  
Arthi V Rao ◽  
Katherine Ross ◽  
Michael A Diefenbach

For many people with a recent history of cancer, their cancer experience intrudes into various aspects of daily life. The neighborhood in which one lives can impact how much cancer intrudes into their life.


2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 8507-8507 ◽  
Author(s):  
D. L. Barton ◽  
C. Loprinzi ◽  
D. Wender ◽  
R. Dalton ◽  
E. Balcueva ◽  
...  

8507 Background: Problems with sexual functioning are an issue negatively affecting the quality of life of female cancer survivors. Testosterone has been implicated as an important hormone in sexual functioning such as libido. Studies of transdermal testosterone have shown benefit in enhancing libido in women who have been diagnosed with hypoactive sexual desire disorder after bilateral oophorectomy. This phase III placebo-controlled clinical trial evaluated whether transdermal testosterone would increase libido in female cancer survivors. Methods: Women with a history of cancer, currently without evidence of disease, were eligible if they reported a decrease in sexual desire and had a sexual partner. Women must have been postmenopausal. Eligible women were randomized to receive 2% testosterone in Vanicream (10 mg daily) versus placebo Vanicream for four weeks, then crossed over to the opposite treatment. The primary endpoint, libido, was measured via the desire subscales of the Changes in Sexual Functioning Questionnaire (CSFQ), which were completed at baseline and at the end of 4 and 8 weeks of treatment. The primary endpoint was the average intra-patient change from baseline to four weeks in the CSFQ subscales between the two arms. A total of 64 patients per group were needed to provide 80% power to detect a difference of 8 units between the treatment means. Two-sided alternative hypothesis testing and a 5% Type I error rate were used. Results: One hundred fifty women were enrolled onto this study. Complete data were available for 132 women. For those on active testosterone cream, serum bioavailable testosterone levels increased significantly over placebo, with a mean change from baseline of 12 and 10 ng/dl for the first and second period, respectively (p<.0001). The average intra-patient change from baseline to week 4 in libido was 5.5 on testosterone and 4.4 on placebo (p=0.58). No carryover effect was detected. The difference in average intra-patient changes from baseline for the entire crossover design between the two arms was only 1.1 points (95% confidence interval of -1.2 to 3.4, p=0.35). Conclusion: Testosterone is not a panacea for libido troubles in women with a history of cancer. Further studies are needed to determine whether there is a role for transdermal testosterone in this population. No significant financial relationships to disclose.


2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e24040-e24040
Author(s):  
Changchuan Jiang ◽  
Haowei Wang ◽  
Lei Deng ◽  
Qian Wang ◽  
Xuesong Han ◽  
...  

e24040 Background: The smoking rate has been declining in the United States. Smoking cessation is a critical part of cancer survivorship care. Males have higher smoking rate than females in the general population. However, it remains unclear if cancer status modified the effect of gender on smoking rates. Methods: To evaluate the long-term pattern of smoking prevalence among female cancer survivors, we used the National Health Interview Survey 2000-2017 to estimate the age-adjusted current smoking rates among cancer survivors and participants without a history of cancer for men and women separately. Multivariable linear regression was used to estimate age-adjusted smoking rate in each group, using the US 2010 Census as the standardization population. We also used multivariable logistic regression to examine the whether cancer history modified the influence of gender on current smoking rate. All statistical analyses were performed with SAS 9.4 and accounted for NHIS survey design. Results: Of 526,547 participants, we identified 32,091 cancer survivors, including 11,642 male and 20,449 female cancer survivors. Male cancer survivors had a slightly lower smoking rates than non-cancer male participants (cancer survivors: 16.2%-29.7% vs non-cancer participants: 16.8%-24.4%; OR = 0.94, 95%CI 0.88-1.00, p = 0.05) after adjusting age and year of survey. However, female cancer survivors had a significant higher prevalence of smoking compared with non-cancer female participants (cancer survivors: 20.1-32.6% vs non-cancer participants: women: 12.8%-20.4%; OR = 1.45, 95%CI 1.38-1.52, p < 0.001) during the same period. The gaps in smoking prevalence between female cancer survivors and male cancer survivors were more significant than the gaps between male non-cancer participants and female non-cancer participants from 2000 to 2017 (p interaction < 0.001). Conclusions: Although more men smoke among people without a history of cancer, female survivors had a higher age-adjusted smoking rate than their male counterparts. Effective smoking cessation interventions need to target female survivors as well as male survivors. A gender-sensitive approach is required to address their specific needs in smoking cessation. [Table: see text]


2020 ◽  
Author(s):  
Beatriz León-Salas ◽  
Edurne Zabaleta-del-Olmo ◽  
Joan LLobera ◽  
Bonaventura Bolíbar-Ribas ◽  
Tomas López-Jiménez ◽  
...  

Abstract Objective: To compare the presence of comorbidities and self-perceived health and social support between long-term cancer survivors and people without a history of cancer from a clinical trial examining the effects of a multiple risk behavior intervention.Results: Of the 4259 people studied, 190 (4.46%) were cancer survivors. They had a mean ± SD age of 62.8±7 years vs. 58.7±8 years (P<0.01) for non-cancer people and were more likely to be on long-term sick leave (11.9% vs. 3.5%, P<0.001). No differences were observed for smoking, adherence to the Mediterranean diet, physical activity, obesity, or social support. Cancer survivors were more likely to have worse self-perceived health (OR 1.82; 95% CI 1.02–2.75), more comorbidities (OR 1.68; 95% CI 1.18–2.39), COPD (OR 2.17; 95% CI 1.25–3.78), and depression (OR 1.65; 95% CI 1.06–2.57). Older age and worse self-perceived health were independent predictors of survivorship in the adjusted analysis.


2021 ◽  
Author(s):  
Marta Linares-Moya ◽  
Janet Rodríguez-Torres ◽  
Alejandro Heredia-Ciuró ◽  
María Granados-Santiago ◽  
Laura López-López ◽  
...  

Abstract Purpose Patients with lung cancer experience a variety of distressing symptoms which could adversely quality of life. The aim of this study was to determine whether psychological distress prior to surgery is associated with health status and symptom burden in lung cancer survivors. Methods A longitudinal observational study with one-year follow‐up was carried out. Health status was measured by the WHO Disability Assessment Scale (WHO-DAS 2.0), the Euroqol-5 dimensions (EQ-5D) and the Pittsburgh Sleep Quality Index (PSQI). Symptoms severity included dyspnoea (Multidimensional Profile of Dyspnoea); pain (Brief Pain Inventory); fatigue (Fatigue Severity Scale) and cough (Leicester Cough Questionnaire). Results 174 lung cancer patients were included. Patients in the group with psychological distress presented a worse self-perceived health status, functionality and sleep quality. The group with psychological distress also presented higher dyspnea, fatigue and pain. Conclusion Patients with psychological distress prior surgery present a greater symptom burden and a poorer self-perceived health status, lower functionality and sleep quality, than patients without distress one year after the lung resection.


2009 ◽  
Vol 3 (3) ◽  
pp. 164-173 ◽  
Author(s):  
Melissa S. Y. Thong ◽  
Floortje Mols ◽  
Jan-Willem W. Coebergh ◽  
Jan A. Roukema ◽  
Lonneke V. van de Poll-Franse

Author(s):  
Marta Linares-Moya ◽  
Janet Rodríguez-Torres ◽  
Alejandro Heredia-Ciuró ◽  
María Granados-Santiago ◽  
Laura López-López ◽  
...  

Abstract Purpose Patients with lung cancer experience a variety of distressing symptoms which could adversely affect quality of life. The aim of this study was to determine whether psychological distress prior to surgery is associated to health status and symptom burden in lung cancer survivors. Methods A longitudinal observational study with 1‐year follow‐up was carried out. Health status was measured by the WHO Disability Assessment Scale (WHO-DAS 2.0), the Euroqol-5 dimensions (EQ-5D) and the Pittsburgh Sleep Quality Index (PSQI). Symptoms severity included dyspnoea (Multidimensional Profile of Dyspnoea); pain (Brief Pain Inventory); fatigue (Fatigue Severity Scale); and cough (Leicester Cough Questionnaire). Results One hundred seventy-four lung cancer patients were included. Patients in the group with psychological distress presented a worse self-perceived health status, functionality and sleep quality. The group with psychological distress also presented higher dyspnoea, fatigue and pain. Conclusion Patients with psychological distress prior surgery present with a greater symptom burden and a poorer self-perceived health status, lower functionality and sleep quality, than patients without distress 1 year after the lung resection.


Sign in / Sign up

Export Citation Format

Share Document